Emergent BioSolutions (EBS) Tops Q3 EPS by 32c; Says FY16 Outlook Still Postponed

Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $0.58, $0.32 better than the analyst estimate of $0.26. Revenue for the quarter came in at $142.9 million versus the consensus estimate of $112.3 million.

The Company continues to postpone its financial guidance for 2016 until the CDC follow-on BioThrax® procurement contract has been finalized.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.

You May Also Be Interested In

• Birkenstock Holding (BIRK) Misses Q3 EPS by 2c; lifts guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c
• Southland Holdings (SLND) Misses Q2 EPS by 122c